Company
Melbourne, VIC
Every investor coverage indicates participated in a round Q-Sera raised.
Investors whose own portfolio pages list Q-Sera, even though we haven't found any coverage of the round yet.
Companies Q-Sera acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Michael Grant | CEO | Uniseed |
Stories naming Q-Sera. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Uniseed-backed Australian medtech Q-Sera's blood-clotting tube technology has debuted in Japan via Terumo's VenoJect II launch; the post also credits MRCF and UniQuest Extension Fund as backers.
Q-Sera's RAPClot blood-collection tube has debuted commercially in Japan, its first market launch, announced via a press release posted on Uniseed's news page.
Brandon Capital has completed a A$439 million final close for its sixth life sciences fund, bringing the National Reconstruction Fund Corporation and WA Government in alongside backers such as HESTA, Hostplus, CSL and QIC.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Cut Through Venture·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·Forbes Australia·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com·Forbes Australia
Venture fund Uniseed led a million-dollar slice of probiotic drinks maker PERKii's four-million-dollar round, its first deal from its new $50 million fund, to fund a national launch.
University of Queensland spin-out Q-Sera has banked $900,000 from MRCF and Uniseed to develop snake venom-based blood collection tubes; the piece also recalls Vaxxas's $15 million round.